Dialectic Therapeutics issued an SEC Form D to confirm the sale of nearly $6.4 million in debt, options, warrants and/or other rights to purchase securities.
According to the filing, the Dallas-based cancer treatment technology developer made the first sale in its offering of $6.35 million on Dec. 15, 2020. The $6.35 million already sold is the total amount being offered.
In total, 27 investors contributed to the amended offering, which is not being made in connection with a merger, acquisition or another form of business combination transaction.
The minimum investment accepted by Dialectic Therapeutics was $50,000. The company confirmed that $100,000 of the proceeds collected in the offering is earmarked for payments to a number of executive officers, directors or promoters. No other intended use of proceeds was listed.
Dialectic Therapeutics is a pre-clinical biotechnology company developing anti-cancer drugs with limited toxicities and complications for treating patients with few to no other options, according to the company’s website.
Tell Us What You Think!
You must be logged in to post a comment.